EVFM OTC
Evofem Biosciences, Inc.
1W: -3.9%
1M: -7.5%
3M: -22.1%
YTD: -22.1%
1Y: -44.8%
3Y: -94.7%
5Y: -100.0%
$0.01
+0.00 (+10.81%)
Weekly Expected Move ±7.8%
$0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
88 relationships67
As Filer
counterparties named
21
As Counterparty
mentioned by others
7
Rel. Types
2022-02-16
Earliest Filing
2025-10-17
Latest Filing
target: 19
acquirer: 19
investor: 12
partner: 7
licensee: 6
customer: 2
supplier: 2
Counterparties (Filed by EVFM)
67 relationshipsCompanies named in EVFM's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Evofem Biosciences, Inc. | EVFM | target | Company issuing convertible promissory notes and entering into amendment | 2025-10-17 | View |
| Adjuvant Global Health Technology Fund, L.P. | — | investor | Purchaser of convertible promissory notes | 2025-10-17 | View |
| Adjuvant Global Health Technology Fund DE, L.P. | — | investor | Purchaser of convertible promissory notes | 2025-10-17 | View |
| Evofem Biosciences, Inc. | EVFM | licensee | Licensor granting exclusive license for 5-nitroimidazole product | 2025-05-22 | View |
| Evofem Biosciences Operations, Inc. | EVFM | partner | Wholly owned subsidiary of Evofem Biosciences, Inc. | 2025-05-22 | View |
| Evofem, Inc. | EVFM | partner | Wholly owned subsidiary of Evofem Biosciences, Inc. | 2025-05-22 | View |
| Pharma 1 Drug Store L.L.C. | — | licensee | Licensee obtaining exclusive rights to market product in Middle East | 2025-05-22 | View |
| Evofem Biosciences, Inc. | EVFM | licensee | Licensor granting exclusive license for development and supply of Licensed Product | 2025-05-08 | View |
| Pharma 1 Drug Store L.L.C. | — | licensee | Licensee granted exclusive rights to develop, market, and distribute Licensed Product in the Territory | 2025-05-08 | View |
| Evofem Biosciences, Inc. | EVFM | customer | Buyer in a License and Supply Agreement amendment | 2025-04-03 | View |
| Windtree Therapeutics, Inc. | WINTW | supplier | Supplier in a License and Supply Agreement amendment | 2025-04-03 | View |
| Evofem Biosciences, Inc. | EVFM | customer | Buyer in the License and Supply Agreement | 2025-03-26 | View |
| Windtree Therapeutics, Inc. | WINTW | supplier | Supplier in the License and Supply Agreement | 2025-03-26 | View |
| Adifem, Inc. | — | acquirer | Merger Sub in merger agreement | 2024-11-25 | View |
| Aditxt, Inc. | ADTX | acquirer | Parent company in merger agreement | 2024-11-25 | View |
| Evofem Biosciences, Inc. | EVFM | target | Target company in merger agreement | 2024-11-25 | View |
| Aditxt, Inc. | ADTX | acquirer | Proposed merger target and investor providing Series F-1 convertible preferred stock | 2024-11-06 | View |
| Adifem, Inc. | — | target | Subsidiary of Aditxt, Inc. being merged into Evofem Biosciences, Inc. | 2024-11-06 | View |
| Adifem, Inc. | — | acquirer | Merger Sub entity entering into a Support Agreement for the merger of Evofem Biosciences, Inc. | 2024-10-31 | View |
| Evofem Biosciences, Inc. | EVFM | target | Target company whose stockholders are entering into a Support Agreement for the merger. | 2024-10-31 | View |
| Aditxt, Inc. | ADTX | acquirer | Parent company entering into a Support Agreement for the merger of Evofem Biosciences, Inc. | 2024-10-31 | View |
| Aditxt, Inc. | ADTX | investor | Purchaser of Series F-1 Convertible Preferred Stock | 2024-10-28 | View |
| Evofem Biosciences, Inc. | EVFM | target | Issuer of Series F-1 Convertible Preferred Stock | 2024-10-28 | View |
| Aditxt, Inc. | ADTX | investor | Buyer purchasing Series F-1 Convertible Preferred Stock | 2024-10-03 | View |
| Evofem Biosciences, Inc. | EVFM | partner | Company issuing Series F-1 Convertible Preferred Stock | 2024-10-03 | View |
| Aditxt, Inc. | ADTX | investor | Buyer purchasing Series F-1 Convertible Preferred Stock | 2024-09-25 | View |
| Evofem Biosciences, Inc. | EVFM | partner | Company issuing Series F-1 Convertible Preferred Stock | 2024-09-25 | View |
| Aditxt, Inc. | ADTX | acquirer | Parent company entering merger agreement | 2024-09-06 | View |
| Evofem Biosciences, Inc. | EVFM | target | Target company being acquired in merger | 2024-09-06 | View |
| Adifem, Inc. | — | acquirer | Merger Sub entity entering merger agreement | 2024-09-06 | View |
| Aditxt, Inc. | ADTX | acquirer | Parent company entering merger agreement | 2024-08-20 | View |
| Adifem, Inc. | — | acquirer | Merger Sub entity entering merger agreement | 2024-08-20 | View |
| Evofem Biosciences, Inc. | EVFM | target | Target company being acquired in the merger | 2024-08-20 | View |
| Pharma 1 Drug Store L.L.C. | — | licensee | Licensee obtaining exclusive rights to develop and market product in Middle East | 2024-07-23 | View |
| Evofem, Inc. | EVFM | partner | Wholly owned subsidiary of Evofem Biosciences, Inc. | 2024-07-23 | View |
| Evofem Biosciences Operations, Inc. | EVFM | partner | Wholly owned subsidiary of Evofem Biosciences, Inc. | 2024-07-23 | View |
| Evofem Biosciences, Inc. | EVFM | licensee | Licensor granting exclusive license for contraceptive product in Middle East | 2024-07-23 | View |
| Adifem, Inc. | — | acquirer | Merger subsidiary of Aditxt, Inc. used to acquire Evofem Biosciences, Inc. | 2024-07-18 | View |
| Evofem Biosciences, Inc. | EVFM | target | Target company being acquired by Aditxt, Inc. in a merger transaction. | 2024-07-18 | View |
| EVOFEM BIOSCIENCES, INC. | EVFM | acquirer | Buyer in asset purchase agreement | 2024-07-18 | View |
| LUPIN INC. | — | target | Seller in asset purchase agreement | 2024-07-18 | View |
| Aditxt, Inc. | ADTX | acquirer | Parent company acquiring Evofem Biosciences, Inc. in a merger transaction. | 2024-07-18 | View |
| Aditxt, Inc. | ADTX | acquirer | Parent company entering into reinstated merger agreement | 2024-05-02 | View |
| Evofem Biosciences, Inc. | EVFM | target | Target company in the merger agreement | 2024-05-02 | View |
| Adifem, Inc. | — | target | Merger subsidiary (formerly Adicure, Inc.) | 2024-05-02 | View |
| Adicure, Inc. | — | target | Merger subsidiary entering merger agreement amendment | 2024-03-06 | View |
| Aditxt, Inc. | ADTX | acquirer | Parent company entering merger agreement amendment | 2024-03-06 | View |
| Evofem Biosciences, Inc. | EVFM | target | Company entering merger agreement amendment | 2024-03-06 | View |
| Adicure, Inc. | — | target | Merger Sub in the merger agreement | 2024-01-31 | View |
| Evofem Biosciences, Inc. | EVFM | target | Company in the merger agreement | 2024-01-31 | View |
| Aditxt, Inc. | ADTX | acquirer | Parent company in the merger agreement | 2024-01-31 | View |
| Aditxt, Inc. | ADTX | acquirer | Parent company in the merger agreement | 2024-01-11 | View |
| Adicure, Inc. | — | target | Merger Sub in the merger agreement | 2024-01-11 | View |
| Evofem Biosciences, Inc. | EVFM | target | Company in the merger agreement | 2024-01-11 | View |
| Aditxt, Inc. | ADTX | acquirer | Aditxt, Inc. is the parent company acquiring Evofem Biosciences, Inc. in a merger transaction. | 2023-12-27 | View |
| Adicure, Inc. | — | acquirer | Adicure, Inc. is the parent company of Merger Sub, which will merge with Evofem Biosciences, Inc. | 2023-12-27 | View |
| Aditxt, Inc. | ADTX | acquirer | Parent company acquiring Evofem Biosciences, Inc. in a merger transaction. | 2023-12-12 | View |
| Evofem Biosciences, Inc. | EVFM | target | Target company being acquired in the merger with Adicure, Inc. | 2023-12-12 | View |
| Adicure, Inc. | — | partner | Wholly-owned subsidiary of Aditxt, Inc. used as the merger vehicle. | 2023-12-12 | View |
| Baker Bros. Advisors LP | — | investor | Designated Agent and investment adviser for Purchasers | 2023-09-11 | View |
| Baker Bros. Life Sciences, L.P. | — | investor | Purchaser of convertible promissory notes and warrants | 2023-09-11 | View |
| 667, L.P. | — | investor | Purchaser of convertible promissory notes and warrants | 2023-09-11 | View |
| Evofem Biosciences, Inc. | EVFM | target | Company entering into amendment to securities purchase agreement | 2023-09-11 | View |
| Adjuvant Global Health Technology Fund, LP | — | investor | Purchaser of convertible promissory notes and party to the First Amendment to the Securities Purchase Agreement. | 2022-04-07 | View |
| Adjuvant Global Health Technology Fund, DE, LP | — | investor | Purchaser of convertible promissory notes and party to the First Amendment to the Securities Purchase Agreement. | 2022-04-07 | View |
| Seven Knots, LLC | — | investor | Agreed to purchase up to $50 million of common stock over a period up to March 1, 2024. | 2022-02-16 | View |
| Seven Knots, LLC | — | investor | Agreed to purchase up to $50 million of Evofem Biosciences common stock over a period up to March 1, 2024. | 2022-02-16 | View |
Mentioned As Counterparty
21 mentionsOther companies that named EVFM in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| ADTX Aditxt, Inc. | acquirer | Target company in merger agreement | 2025-08-27 | View |
| ADTX Aditxt, Inc. | investor | Aditxt purchased a senior subordinated convertible note and warrant from Evofem Biosciences, Inc. | 2025-07-01 | View |
| ADTX Aditxt, Inc. | acquirer | Target of merger agreement and recipient of equity investment and notes. | 2025-06-09 | View |
| ADTX Aditxt, Inc. | acquirer | Issuer of securities subject to the call option agreement | 2025-04-15 | View |
| ADTX Aditxt, Inc. | investor | Aditxt purchased a senior subordinated convertible note and warrant from Evofem. | 2025-04-09 | View |
| ADTX Aditxt, Inc. | acquirer | Target company in merger agreement receiving equity investment | 2025-03-24 | View |
| ADTX Aditxt, Inc. | acquirer | Target company in merger agreement to be merged into Merger Sub | 2024-11-19 | View |
| ADTX Aditxt, Inc. | investor | Aditxt, Inc. purchased Series F-1 Convertible Preferred Stock from Evofem Biosciences, Inc. | 2024-10-30 | View |
| ADTX Aditxt, Inc. | acquirer | Target of merger agreement and counterparty to securities purchase agreement for preferred stock. | 2024-10-03 | View |
| ADTX Aditxt, Inc. | partner | Purchased Series F-1 Convertible Preferred Stock and entered into a Market Development Collaboration Agreement. | 2024-09-23 | View |
| ADTX Aditxt, Inc. | acquirer | Target company in merger agreement and recipient of parent equity investments. | 2024-09-06 | View |
| ADTX Aditxt, Inc. | acquirer | Target of merger and recipient of Series F-1 Convertible Preferred Stock investment | 2024-08-13 | View |
| ADTX Aditxt, Inc. | acquirer | Target company in the merger with Aditxt, Inc. and investor in Aditxt, Inc.'s Series F-1 Preferred Stock. | 2024-07-18 | View |
| ADTX Aditxt, Inc. | partner | Target company in the Merger Agreement | 2024-06-21 | View |
| ADTX Aditxt, Inc. | acquirer | Target company in the merger agreement with Aditxt, Inc. | 2024-05-03 | View |
| ADTX Aditxt, Inc. | acquirer | Target company in the merger with Aditxt, Inc.'s subsidiary. | 2024-03-04 | View |
| ADTX Aditxt, Inc. | acquirer | Target company in a merger agreement with Adicure, Inc. | 2024-02-02 | View |
| ADTX Aditxt, Inc. | acquirer | Target of merger agreement | 2024-01-09 | View |
| ADTX Aditxt, Inc. | acquirer | Target of a merger with a wholly owned subsidiary of Aditxt, Inc. | 2024-01-02 | View |
| ADTX Aditxt, Inc. | partner | Target company in the merger agreement with Aditxt | 2023-12-26 | View |
| ADTX Aditxt, Inc. | acquirer | Delaware corporation acquired by Aditxt, Inc. via merger with Adicure, Inc. | 2023-12-12 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-23 | Material Agreement; Exhibits | Agreement | View |
| 2026-07-20 | Regulation FD; Exhibits | View | |
| 2026-07-14 | Material Agreement; Financial Obligation; Exhibits | Agreement | View |
| 2026-05-18 | Earnings Release; Exhibits | View | |
| 2026-04-30 | Material Agreement; Regulation FD; Exhibits | Agreement | View |
| 2026-04-16 | Material Agreement; Exhibits | Agreement | View |
| 2026-03-11 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2026-01-12 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-11-26 | Amendments to Articles of Incorporation or Bylaws; Submission of Matters to a Vote of Security Holde | View | |
| 2025-11-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-20 | Termination of Material Definitive Agreement; Submission of Matters to a Vote of Security Holders; R | View | |
| 2025-10-17 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-08-26 | Entry into Material Definitive Agreement; Material Modification to Rights of Security Holders; Amend | Agreement | View |
| 2025-08-14 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-07-02 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Financial Stateme | Agreement | View |
| 2025-05-22 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
| 2025-05-15 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-05-08 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-04-14 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-04-03 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR